
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5680623/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Central Effects of the Designer Drug Mephedrone in Mice—Basic Studies. Brain Sciences, 2022, 12, 189.	2.3	5
2	Activation of the 5-HT7 receptor and MMP-9 signaling module in the hippocampal CA1 region is necessary for the development of depressive-like behavior. Cell Reports, 2022, 38, 110532.	6.4	18
3	Antidepressant-like Effects of Combined Fluoxetine and Zinc Treatment in Mice Exposed to Chronic Restraint Stress Are Related to Modulation of Histone Deacetylase. Molecules, 2022, 27, 22.	3.8	5
4	Zinc Deficiency Blunts the Effectiveness of Antidepressants in the Olfactory Bulbectomy Model of Depression in Rats. Nutrients, 2022, 14, 2746.	4.1	2
5	Vorinostat (SAHA) May Exert Its Antidepressant-Like Effects Through the Modulation of Oxidative Stress Pathways. Neurotoxicity Research, 2021, 39, 170-181.	2.7	3
6	The Interaction of Selective A1 and A2A Adenosine Receptor Antagonists with Magnesium and Zinc Ions in Mice: Behavioural, Biochemical and Molecular Studies. International Journal of Molecular Sciences, 2021, 22, 1840.	4.1	5
7	Synthesis of Novel Pyrido[1,2-c]pyrimidine Derivatives with 6-Fluoro-3-(4-piperidynyl)-1,2-benzisoxazole Moiety as Potential SSRI and 5-HT1A Receptor Ligands. International Journal of Molecular Sciences, 2021, 22, 2329.	4.1	8
8	N-Skatyltryptamines—Dual 5-HT6R/D2R Ligands with Antipsychotic and Procognitive Potential. Molecules, 2021, 26, 4605.	3.8	3
9	Influence of Incorporation of Different dn-Electron Metal Cations into Biologically Active System on Its Biological and Physicochemical Properties. International Journal of Molecular Sciences, 2021, 22, 12909.	4.1	3
10	Imipramine Influences Body Distribution of Supplemental Zinc Which May Enhance Antidepressant Action. Nutrients, 2020, 12, 2529.	4.1	12
11	Ketamine and Ro 25-6981 Reverse Behavioral Abnormalities in Rats Subjected to Dietary Zinc Restriction. International Journal of Molecular Sciences, 2020, 21, 4791.	4.1	5
12	An update on NMDA antagonists in depression. Expert Review of Neurotherapeutics, 2019, 19, 1055-1067.	2.8	39
13	Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands. European Journal of Medicinal Chemistry, 2019, 180, 383-397.	5.5	11
14	Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect. European Journal of Medicinal Chemistry, 2019, 183, 111736.	5.5	21
15	Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands. European Journal of Medicinal Chemistry, 2019, 166, 144-158.	5.5	14
16	Antidepressant-like activity of hyperforin and changes in BDNF and zinc levels in mice exposed to chronic unpredictable mild stress. Behavioural Brain Research, 2019, 372, 112045.	2.2	33
17	Characterization of the Brain Penetrant Neuropeptide Y Y2 Receptor Antagonist SF-11. ACS Chemical Neuroscience, 2019, 10, 3454-3463.	3.5	7
18	The role of magnesium and zinc in depression: similarities and differences. Magnesium Research, 2018, 31, 78-89.	0.5	24

#	Article	IF	CITATIONS
19	Hyperforin Potentiates Antidepressant-Like Activity of Lanicemine in Mice. Frontiers in Molecular Neuroscience, 2018, 11, 456.	2.9	29
20	Chronic antidepressant-like effect of EMD386088, a partial 5-HT6 receptor agonist, in olfactory bulbectomy model may be connected with BDNF and/or CREB signalling pathway. Pharmacological Reports, 2018, 70, 1047-1056.	3.3	5
21	Zinc and copper concentration do not differentiate bipolar disorder from major depressive disorder. Psychiatria Polska, 2018, 52, 449-457.	0.5	6
22	Antidepressant activity of zinc: Further evidence for the involvement of the serotonergic system. Pharmacological Reports, 2017, 69, 456-461.	3.3	6
23	The role of zinc deficiency-induced changes in the phospholipid-protein balance of blood serum in animal depression model by Raman, FTIR and UV–vis spectroscopy. Biomedicine and Pharmacotherapy, 2017, 89, 549-558.	5.6	22
24	Antidepressant-like activity of the neuropeptide Y Y5 receptor antagonist Lu AA33810: behavioral, molecular, and immunohistochemical evidence. Psychopharmacology, 2017, 234, 631-645.	3.1	16
25	Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats. Neuropharmacology, 2017, 125, 333-342.	4.1	32
26	The serum zinc concentration as a potential biological marker in patients with major depressive disorder. Metabolic Brain Disease, 2017, 32, 97-103.	2.9	36
27	Associations of Serum Cytokine Receptor Levels with Melancholia, Staging of Illness, Depressive and Manic Phases, and Severity of Depression in Bipolar Disorder. Molecular Neurobiology, 2017, 54, 5883-5893.	4.0	46
28	The level of the zinc homeostasis regulating proteins in the brain of rats subjected to olfactory bulbectomy model of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 72, 36-48.	4.8	14
29	Nitric Oxide Synthase Inhibitor Attenuates the Effects of Repeated Restraint Stress on Synaptic Transmission in the Paraventricular Nucleus of the Rat Hypothalamus. Frontiers in Cellular Neuroscience, 2017, 11, 127.	3.7	5
30	The serum concentration of copper in bipolar disorder. Psychiatria Polska, 2017, 51, 469-481.	0.5	18
31	Thiobarbituric Acid-Reactive Substances: Markers of an Acute Episode and a Late Stage of Bipolar Disorder. Neuropsychobiology, 2016, 73, 116-122.	1.9	29
32	Zinc transporters protein level in postmortem brain of depressed subjects and suicide victims. Journal of Psychiatric Research, 2016, 83, 220-229.	3.1	29
33	Study of the Serum Copper Levels in Patients with Major Depressive Disorder. Biological Trace Element Research, 2016, 174, 287-293.	3.5	46
34	Brain glutamic acid decarboxylase-67kDa alterations induced by magnesium treatment in olfactory bulbectomy and chronic mild stress models in rats. Pharmacological Reports, 2016, 68, 881-885.	3.3	7
35	Concentration-Dependent Dual Mode of Zn Action at Serotonin 5-HT1A Receptors: In Vitro and In Vivo Studies. Molecular Neurobiology, 2016, 53, 6869-6881.	4.0	30
36	Olfactory bulbectomy-induced changes in phospholipids and protein profiles in the hippocampus and prefrontal cortex of rats. A preliminary study using a FTIR spectroscopy. Pharmacological Reports, 2016, 68, 521-528.	3.3	17

#	Article	lF	CITATIONS
37	Decreased serum zinc concentration during depressive episode in patients with bipolar disorder. Journal of Affective Disorders, 2016, 190, 272-277.	4.1	27
38	Alterations of Bio-elements, Oxidative, and Inflammatory Status in the Zinc Deficiency Model in Rats. Neurotoxicity Research, 2016, 29, 143-154.	2.7	30
39	Relationship between Zinc (Zn2+) and Glutamate Receptors in the Processes Underlying Neurodegeneration. Neural Plasticity, 2015, 2015, 1-9.	2.2	39
40	Evaluation of the role of NMDA receptor function in antidepressant-like activity. A new study with citalopram and fluoxetine in the forced swim test in mice. Pharmacological Reports, 2015, 67, 490-493.	3.3	14
41	Antidepressant-like activity of magnesium in the olfactory bulbectomy model is associated with the AMPA/BDNF pathway. Psychopharmacology, 2015, 232, 355-367.	3.1	44
42	Antidepressant-like activity of EMD 386088, a 5-HT6 receptor partial agonist, following systemic acute and chronic administration to rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 1079-1088.	3.0	16
43	Antidepressant activity of fluoxetine in the zinc deficiency model in rats involves the NMDA receptor complex. Behavioural Brain Research, 2015, 287, 323-330.	2.2	27
44	Activation of mTOR dependent signaling pathway is a necessary mechanism of antidepressant-like activity of zinc. Neuropharmacology, 2015, 99, 517-526.	4.1	40
45	Zinc deficiency in rats is associated with up-regulation of hippocampal NMDA receptor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 56, 254-263.	4.8	43
46	The serum concentration of magnesium as a potential state marker in patients with diagnosis of bipolar disorder. Psychiatria Polska, 2015, 49, 1277-1287.	0.5	13
47	The serum magnesium concentration as a potential state marker in patients with unipolar affective disorder. Psychiatria Polska, 2015, 49, 1265-1276.	0.5	10
48	Antidepressant-like activity of magnesium in the chronic mild stress model in rats: alterations in the NMDA receptor subunits. International Journal of Neuropsychopharmacology, 2014, 17, 393-405.	2.1	54
49	Stress-induced alterations in 5-HT1A receptor transcriptional modulators NUDR and Freud-1. International Journal of Neuropsychopharmacology, 2014, 17, 1763-1775.	2.1	24
50	An anti-immobility effect of spermine in the forced swim test in mice. Pharmacological Reports, 2014, 66, 223-227.	3.3	8
51	The involvement of the GPR39-Zn(2+)-sensing receptor in the pathophysiology of depression. Studies in rodent models and suicide victims. Neuropharmacology, 2014, 79, 290-297.	4.1	66
52	NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opinion on Investigational Drugs, 2014, 23, 1181-1192.	4.1	40
53	Antidepressant-like effect of the mGluR5 antagonist MTEP in an astroglial degeneration model of depression. Behavioural Brain Research, 2014, 273, 23-33.	2.2	33
54	Biological consequences of zinc deficiency in the pathomechanisms of selected diseases. Journal of Biological Inorganic Chemistry, 2014, 19, 1069-1079.	2.6	127

#	Article	IF	CITATIONS
55	A standard sample preparation and calibration procedure for imaging zinc and magnesium in rats' brain tissue by laser ablation-inductively coupled plasma-time of flight-mass spectrometry. Journal of Analytical Atomic Spectrometry, 2014, 29, 1425-1431.	3.0	24
56	Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats. Neuropharmacology, 2014, 82, 59-68.	4.1	40
57	Zinc as a marker of affective disorders. Pharmacological Reports, 2013, 65, 1512-1518.	3.3	66
58	Oxidative stress markers in affective disorders. Pharmacological Reports, 2013, 65, 1558-1571.	3.3	110
59	Involvement of NMDA and AMPA receptors in the antidepressant-like activity of antidepressant drugs in the forced swim test. Pharmacological Reports, 2013, 65, 991-997.	3.3	35
60	Zinc, magnesium and NMDA receptor alterations in the hippocampus of suicide victims. Journal of Affective Disorders, 2013, 151, 924-931.	4.1	63
61	Glial degeneration as a model of depression. Pharmacological Reports, 2013, 65, 1572-1579.	3.3	26
62	Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives asÂpotential antidepressant agents. Part 1. European Journal of Medicinal Chemistry, 2013, 63, 484-500.	5.5	33
63	Effects of ifenprodil on the antidepressant-like activity of NMDA ligands in the forced swim test in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 46, 29-35.	4.8	25
64	Zinc homeostasis and neurodegenerative disorders. Frontiers in Aging Neuroscience, 2013, 5, 33.	3.4	235
65	Investigational NMDA receptor modulators for depression. Expert Opinion on Investigational Drugs, 2012, 21, 91-102.	4.1	44
66	A bright future of researching AMPA receptor agonists for depression treatment. Expert Opinion on Investigational Drugs, 2012, 21, 583-585.	4.1	3
67	Anxiolytic-like activity of zinc in rodent tests. Pharmacological Reports, 2011, 63, 1050-1055.	3.3	32
68	The role of zinc in neurodegenerative inflammatory pathways in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 693-701.	4.8	139
69	Synthesis and biological investigation of potential atypical antipsychotics with a tropane core. Part 1. European Journal of Medicinal Chemistry, 2011, 46, 4474-4488.	5.5	12
70	Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in mice. Journal of Neural Transmission, 2011, 118, 857-864.	2.8	16
71	A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. Journal of Neural Transmission, 2011, 118, 1535-1546.	2.8	46
72	The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids, 2010, 39, 205-217.	2.7	77

#	Article	IF	CITATIONS
73	Decreased expression of Freud-1/CC2D1A, a transcriptional repressor of the 5-HT1A receptor, in the prefrontal cortex of subjects with major depression. International Journal of Neuropsychopharmacology, 2010, 13, 1089-1101.	2.1	32
74	Ionic Glutamate Modulators in Depression (Zinc, Magnesium). , 2010, , 21-38.		4
75	Gender-specific decrease in NUDR and 5-HT1A receptor proteins in the prefrontal cortex of subjects with major depressive disorder. International Journal of Neuropsychopharmacology, 2009, 12, 155.	2.1	71
76	The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 323-329.	4.8	117
77	Human Freud-2/CC2D1B: A Novel Repressor of Postsynaptic Serotonin-1A Receptor Expression. Biological Psychiatry, 2009, 66, 214-222.	1.3	36
78	Zinc-induced adaptive changes in NMDA/glutamatergic and serotonergic receptors. Pharmacological Reports, 2009, 61, 1184-1191.	3.3	49
79	Antidepressant-like activity of 8-Br-cAMP, a PKA activator, in the forced swim test. Journal of Neural Transmission, 2008, 115, 829-830.	2.8	13
80	Antidepressant-like activity of zinc: further behavioral and molecular evidence. Journal of Neural Transmission, 2008, 115, 1621-1628.	2.8	110
81	Effects of South African traditional medicine in animal models for depression. Journal of Ethnopharmacology, 2008, 119, 542-548.	4.1	47
82	Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacological Reports, 2008, 60, 588-9.	3.3	105
83	D-serine, a selective glycine/N-methyl-D-aspartate receptor agonist, antagonizes the antidepressant-like effects of magnesium and zinc in mice. Pharmacological Reports, 2008, 60, 996-1000.	3.3	24
84	Effects of GABAB receptor ligands in rodent tests of anxiety-like behavior. Pharmacological Reports, 2007, 59, 757-62.	3.3	26
85	Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. British Journal of Pharmacology, 2006, 149, 581-590.	5.4	60
86	Increase in synaptic hippocampal zinc concentration following chronic but not acute zinc treatment in rats. Brain Research, 2006, 1090, 69-75.	2.2	18
87	The Anxioselective Agent 7-(2-Chloropyridin-4-yl)pyrazolo-[1,5-a]-pyrimidin-3-yl](pyridin-2-yl)methanone (DOV 51892) Is More Efficacious Than Diazepam at Enhancing GABA-Gated Currents at α1 Subunit-Containing GABAA Receptors. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 1244-1252.	2.5	39
88	Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacological Reports, 2006, 58, 427-30.	3.3	34
89	Enhancement of antidepressant-like activity by joint administration of imipramine and magnesium in the forced swim test: Behavioral and pharmacokinetic studies in mice. Pharmacology Biochemistry and Behavior, 2005, 81, 524-529.	2.9	39
90	Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacology Biochemistry and Behavior, 2005, 81, 901-906.	2.9	122

#	Article	IF	CITATIONS
91	Zinc and depression. An update. Pharmacological Reports, 2005, 57, 713-8.	3.3	106
92	Anxiolytic action of group II and III metabotropic glutamate receptors agonists involves neuropeptide Y in the amygdala. Pharmacological Reports, 2005, 57, 734-43.	3.3	11
93	In the Amygdala Anxiolytic Action of mGlu5 Receptors Antagonist MPEP Involves Neuropeptide Y but not GABAA Signaling. Neuropsychopharmacology, 2004, 29, 514-521.	5.4	44
94	Antidepressant- and anxiolytic-like activity of magnesium in mice. Pharmacology Biochemistry and Behavior, 2004, 78, 7-12.	2.9	104
95	Zinc treatment induces cortical brain-derived neurotrophic factor gene expression. European Journal of Pharmacology, 2004, 492, 57-59.	3.5	63
96	Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology, 2004, 46, 151-159.	4.1	125
97	Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Research Bulletin, 2003, 61, 159-164.	3.0	153
98	Reduced potency of zinc to interact with NMDA receptors in hippocampal tissue of suicide victims. Polish Journal of Pharmacology, 2003, 55, 455-9.	0.3	20
99	Involvement of CRF but not NPY in the anxiety regulation via NMDA receptors. Polish Journal of Pharmacology, 2003, 55, 1119-24.	0.3	6
100	Effect of chronic imipramine or electroconvulsive shock on the expression of mGluR1a and mGluR5a immunoreactivity in rat brain hippocampus. Neuropharmacology, 2002, 42, 1016-1023.	4.1	51
101	Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology, 2002, 43, 181-187.	4.1	147
102	Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids, 2002, 23, 213-216.	2.7	61
103	Mechanisms contributing to antidepressant zinc actions. Polish Journal of Pharmacology, 2002, 54, 587-92.	0.3	22
104	Interaction of zinc with antidepressants in the forced swimming test in mice. Polish Journal of Pharmacology, 2002, 54, 681-5.	0.3	42
105	Anxiolytic- and antidepressant-like effects of group III metabotropic glutamate agonist (1S,3R,4S)-1-aminocyclopentane-1,3,4-tricarboxylic acid (ACPT-I) in rats. Polish Journal of Pharmacology, 2002, 54, 707-10.	0.3	29
106	Antidepressant-like properties of zinc in rodent forced swim test. Brain Research Bulletin, 2001, 55, 297-300.	3.0	137
107	The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology, 2001, 158, 94-99.	3.1	84
108	Roles of group II metabotropic glutamate receptors in modulation of seizure activity. Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361, 283-288.	3.0	46

1

#	Article	IF	CITATIONS
109	Stimulation of group II metabotropic glutamate receptors or inhibition of group I ones exerts anxiolytic-like effects in rats. Amino Acids, 2000, 19, 81-86.	2.7	8

110 Zinc Deficiency and Depression. , 0, , .